Standard BioTools (NASDAQ:LAB) is a California-based life science tools company that develops and commercializes microfluidic and mass cytometry systems for single-cell and spatial biology applications. Its core offerings include chip-based molecular biology platforms designed to streamline sample preparation, high-throughput polymerase chain reaction (PCR) assays and secure digital PCR for genomic analysis. Through ongoing investment in research and development, the company aims to address the needs of researchers studying cellular heterogeneity, immune profiling and biomarker discovery.
The company’s product portfolio encompasses microfluidic sample-prep chips, integrated liquid handling instruments and specialized reagents optimized for genomics and proteomics workflows. Key platforms include its single-cell isolation systems, which enable precise capture and processing of individual cells for downstream sequencing or protein analysis. Standard BioTools also provides imaging mass cytometry solutions that combine metal-tagged antibodies with time-of-flight mass spectrometry, allowing high-parameter tissue analysis with subcellular resolution. Complementary software tools support data acquisition, visualization and quantitative analysis for both discovery research and translational studies.
Founded in 1999 under the name Fluidigm by bioengineer Dr. Stephen Quake, the company rebranded as Standard BioTools in 2022 to reflect its broadened focus across multiple single-cell modalities. Headquartered in South San Francisco, it maintains regional offices and distribution channels across North America, Europe and Asia Pacific. Its global customer base spans academic research institutions, pharmaceutical and biotechnology companies, clinical laboratories and government agencies engaged in basic science and drug development programs.
Standard BioTools is guided by an executive leadership team with extensive experience in life science instrumentation, microfluidics engineering and commercial operations. The company’s board of directors includes veteran industry executives and academic thought leaders, positioning Standard BioTools to capitalize on emerging trends in precision medicine, immuno-oncology and systems biology. Through strategic collaborations and a commitment to technological innovation, Standard BioTools seeks to accelerate insights into fundamental biological processes and advance applications in diagnostics and therapeutics.
